Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002
NCT02044627
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperlipidemia
Interventions
DRUG:
[14C-ETC-1002]
Sponsor
Esperion Therapeutics, Inc.